utics Market, The US Market, Annual Cost of Treatment ($), 2010-2018 65Table 41: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2004-2010 66Table 42: Arthritis Therapeutics Market, The US, Treatment Usage Patterns (millions), 2010-2018 66Table 43: Arthritis Therapeutics Market, Top Five EU Countries, Revenue ($bn), 2004-2010 68Table 44: Arthritis Therapeutics Market, Top Five EU Countries, Revenue Forecasts ($bn), 2010-2018 68Table 45: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2004-2010 69Table 46: Arthritis Therapeutics Market, Top Five EU Countries, Annual Cost of Treatment ($), 2010-2018 69Table 47: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2004-2010 70Table 48: Arthritis Therapeutics Market, Top Five EU Countries, Treatment Usage Patterns (millions), 2010-2018 71Table 49: Arthritis Therapeutics Market, Japan, Revenue ($bn), 2004-2010 72Table 50: Arthritis Therapeutics Market, Japan, Revenue Forecast ($bn), 2010-2018 72Table 51: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2004-2010 73Table 52: Arthritis Therapeutics Market, Japan, Annual Cost of Treatment ($), 2010-2018 73Table 53: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2004-2010 74Table 54: Arthritis Therapeutics Market, Japan, Treatment Usage Patterns (millions), 2010-2018 74Table 55: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 79Table 56: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 80Table 57: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Develoment Stage Molecules, 2011 80Table 58: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 2011 81Table 59: Arthritis Therapeutics Market, Osteoarthritis Therapeutics Pipeline, Development Stage Molecules, 201
'/>"/>SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1.
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis2.
The Strong Womans Approach to Managing Rheumatoid Arthritis3.
Defect in A20 gene expression causes rheumatoid arthritis4.
Hospital for Special Surgery to Host International Arthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care5.
CrystalGenomics Initiates CG100649 Phase 2b Study in Patients with Osteoarthritis6.
Interleukin-6 Inhibitor Sirukumab (CNTO 136) Phase 2 Data Show Promise in the Treatment of Active Rheumatoid Arthritis7.
TissueGene Initiates Patient Enrollment for a Phase II Study of TG-C for Osteoarthritis of the Knee8.
Novel ACR Hybrid Score in Rheumatoid Arthritis Applied for the First Time to Data from the RAPID 1 Study with Cimzia® (certolizumab pegol)9.
Arthritis drug could help beat melanoma skin cancer10.
Alder Biopharmaceuticals Announces That Data From Multiple Studies of ALD518 (BMS945429), an Investigational Antibody Therapeutic in Rheumatoid Arthritis Patients, to be Presented at Annual Meeting of the American College of Rheumatology11.
Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis